OCGN
Ocugen, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.36
+0.74%Year over year
Reported trailing growth
- Revenue
- -3.7%
- EBITDA
- -34.4%
- EBIT
- -24.4%
- EPS
- -27.9%
- Free cash flow
- -17.4%
- Operating cash flow
- -18.4%
Forward estimates
Based on analyst estimates
- Revenue
- +21.4%
- EBITDA
- -23.9%
- EPS
- -15.5%
Three-year CAGR
- Revenue
- +21.0%
- EBITDA
- -15.7%
- EBIT
- -14.9%
- Net income
- -25.5%
- EPS
- -15.0%
- Free cash flow
- -25.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026